Tazeen Ahmad
Stock Analyst at B of A Securities
(3.62)
# 825
Out of 5,112 analysts
216
Total ratings
49.04%
Success rate
6.51%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FULC Fulcrum Therapeutics | Maintains: Underperform | $6 → $7 | $12.08 | -42.05% | 7 | Dec 9, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $71 → $112 | $82.07 | +36.47% | 1 | Dec 9, 2025 | |
| PHVS Pharvaris | Maintains: Neutral | $27 → $30 | $24.09 | +24.53% | 5 | Dec 4, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $26 → $29 | $25.20 | +15.08% | 9 | Oct 20, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Buy | $53 | $44.01 | +20.43% | 1 | Oct 9, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $453 → $520 | $392.10 | +32.62% | 5 | Sep 17, 2025 | |
| INCY Incyte | Maintains: Buy | $90 → $104 | $97.63 | +6.52% | 6 | Sep 4, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $227 → $230 | $202.82 | +13.40% | 11 | Sep 2, 2025 | |
| ARGX argenx SE | Maintains: Buy | $880 → $887 | $862.05 | +2.89% | 4 | Sep 2, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Underperform | $17 → $16 | $21.14 | -24.31% | 26 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $76 | $74.94 | +1.41% | 19 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $27 | $26.93 | +0.26% | 16 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $126 → $134 | $91.60 | +46.29% | 9 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $5.44 | +47.06% | 1 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $95 | $111.86 | -15.07% | 9 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $7.13 | +110.38% | 12 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $22 → $4 | $9.43 | -57.58% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $10 → $8 | $9.13 | -12.38% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $27 | $16.81 | +60.62% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $11.72 | +138.91% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $70 | $96.89 | -27.75% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $9.21 | +334.31% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $141.70 | +26.32% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $14.85 | +48.15% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $5.27 | -43.07% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $11.00 | +36.36% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $33.21 | +128.85% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $4.90 | +104.08% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.05 | +471.43% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $13.72 | +9.33% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $3.67 | -45.50% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $1.95 | +207.69% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $20.85 | -28.06% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $265.86 | -77.43% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $3.37 | +374.78% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $175.25 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $22.55 | +1,230.38% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.31 | +289.61% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $26.55 | +80.79% | 6 | Oct 10, 2018 |
Fulcrum Therapeutics
Dec 9, 2025
Maintains: Underperform
Price Target: $6 → $7
Current: $12.08
Upside: -42.05%
Kymera Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $71 → $112
Current: $82.07
Upside: +36.47%
Pharvaris
Dec 4, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $24.09
Upside: +24.53%
Apellis Pharmaceuticals
Oct 20, 2025
Maintains: Neutral
Price Target: $26 → $29
Current: $25.20
Upside: +15.08%
Scholar Rock Holding
Oct 9, 2025
Initiates: Buy
Price Target: $53
Current: $44.01
Upside: +20.43%
Alnylam Pharmaceuticals
Sep 17, 2025
Maintains: Buy
Price Target: $453 → $520
Current: $392.10
Upside: +32.62%
Incyte
Sep 4, 2025
Maintains: Buy
Price Target: $90 → $104
Current: $97.63
Upside: +6.52%
Ascendis Pharma
Sep 2, 2025
Maintains: Buy
Price Target: $227 → $230
Current: $202.82
Upside: +13.40%
argenx SE
Sep 2, 2025
Maintains: Buy
Price Target: $880 → $887
Current: $862.05
Upside: +2.89%
Sarepta Therapeutics
Aug 21, 2025
Maintains: Underperform
Price Target: $17 → $16
Current: $21.14
Upside: -24.31%
Aug 20, 2025
Maintains: Buy
Price Target: $82 → $76
Current: $74.94
Upside: +1.41%
Aug 7, 2025
Maintains: Neutral
Price Target: $23 → $27
Current: $26.93
Upside: +0.26%
Aug 5, 2025
Maintains: Buy
Price Target: $126 → $134
Current: $91.60
Upside: +46.29%
Jul 11, 2025
Initiates: Buy
Price Target: $8
Current: $5.44
Upside: +47.06%
Jul 10, 2025
Maintains: Buy
Price Target: $73 → $95
Current: $111.86
Upside: -15.07%
Jul 1, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $7.13
Upside: +110.38%
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $9.43
Upside: -57.58%
May 19, 2025
Maintains: Underperform
Price Target: $10 → $8
Current: $9.13
Upside: -12.38%
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $16.81
Upside: +60.62%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $11.72
Upside: +138.91%
Mar 10, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $96.89
Upside: -27.75%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $9.21
Upside: +334.31%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $141.70
Upside: +26.32%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $14.85
Upside: +48.15%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $5.27
Upside: -43.07%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $11.00
Upside: +36.36%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $33.21
Upside: +128.85%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $4.90
Upside: +104.08%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.05
Upside: +471.43%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $13.72
Upside: +9.33%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $3.67
Upside: -45.50%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $1.95
Upside: +207.69%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $20.85
Upside: -28.06%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $265.86
Upside: -77.43%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $3.37
Upside: +374.78%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $175.25
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $22.55
Upside: +1,230.38%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.31
Upside: +289.61%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $26.55
Upside: +80.79%